Combination therapy was associated with a lower risk of primary composite outcomes of all-cause hospitalization, all-cause mortality, major adverse cardiovascular events (MACE), major adverse kidney events (MAKE), and major adverse liver outcomes (MALO) (hazard ratio [HR], 0.87
DHA (docosahexaenoic acid) increases BDNF levels and EPA (eicosapentaenoic acid) reduces inflammatory brain markers
In Phase 3 TRIUMPH-1 data, dysesthesia occurred in 5.1%, 12.3%, and 12.5% of participants taking retatrutide 4 mg, 9 mg, and 12 mg, compared with 0.9% of participants receiving placebo
Support and Service: Researchers may contact Xcel Peptides dedicated service team by email, and may expect a response in as little as one business day